All In Biotech

Investigational drug · Phase 3

sustained-release gemcitabine-docetaxel

Also called: NDV-01

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder.

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3

Any phase or sponsor naming "sustained-release gemcitabine-docetaxel"

First trial start

2027

Feb 2027

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "sustained-release gemcitabine-docetaxel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Bladder (Urothelial, Transitional Cell) Cancer
  • Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
  • Urothelial Carcinoma Bladder
  • Urothelial Carcinoma Recurrent
  • Urologic Cancer

Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "sustained-release gemcitabine-docetaxel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Bladder (Urothelial, Transitional Cell) Cancer

  • TARA-002Phase 33 trials

    Protara Therapeutics · Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.